Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Enough? Watchdog's Basic Approach Is Sound, But More Transparency Is Urged

This article was originally published in The Pink Sheet Daily

Executive Summary

An independent report into how NICE values medicines concludes that the basis of its cost-effectiveness assessment is sound, but can be improved. And more transparency would help.
Advertisement

Related Content

NICE To Lose Cost Watch-dog Status By 2013
NICE Likely To Lose Cost-Watchdog Status By 2013
NICE To Lose Cost Watch-dog Status By 2013
NICE Likely To Lose Cost-Watchdog Status By 2013
NICE Likely To Lose Cost-Watchdog Status By 2013
NICE Likely To Lose Cost-Watchdog Status By 2013
NICE Rejects Vidaza, But Celgene Plans Comparator-Based Appeal
Defining Innovation: UK's NICE Responds To Recent Criticism Over Its Methods
The Cost-Sharing Solution: The New NICE Ticket
The Cost-Sharing Solution: The New NICE Ticket

Topics

Advertisement
UsernamePublicRestriction

Register

PS069739

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel